American Academy of Pediatrics and other medical experts exclusively recommend to breastfeed the baby for first 6 months. Once you introduce baby to other foods it is recommended to breastfeed for at least first year of babys life. Taking medication while breastfeeding could be tricky as most drugs pass in breast milk. In this article we will evaluate Simvastatin | Mckesson Packaging Services A Business Unit Of Mckesson Corporation for its safety in breastfeeding.
What is Simvastatin | Mckesson Packaging Services A Business Unit Of Mckesson Corporation ?
Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin tablets can be started simultaneously with diet. Simvastatin is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of total mortality by reducing CHD deaths and reduce the risk of non-fatal myocardial infarction, stroke, and the need for revascularization procedures in patients at high risk of coronary events. (1.1) Reduce elevated total-C, LDL-C, Apo B, TG and increase HDL-C in patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia. (1.2) Reduce elevated TG in patients with hypertriglyceridemia and reduce TG and VLDL-C in patients with primary dysbetalipoproteinemia. (1.2) Reduce total-C and LDL-C in adult patients with homozygous familial hypercholesterolemia. (1.2) Reduce elevated total-C, LDL-C, and Apo B in boys and postmenarchal girls, 10 to 17 years of age with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. (1.2, 1.3) Limitations of Use Simvastatin has not been studied in Fredrickson Types I and V dyslipidemias. (1.4) 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10 to 17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains ≥ 190 mg/dL; or LDL cholesterol remains ≥ 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C < 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin has not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V).
Can I use Simvastatin | Mckesson Packaging Services A Business Unit Of Mckesson Corporation while breastfeeding?
As Simvastatin | Mckesson Packaging Services A Business Unit Of Mckesson Corporation is made of only Simvastatin, and Simvastatin is unsafe to use in breastfeeding we can safely reach on conclusion that Simvastatin | Mckesson Packaging Services A Business Unit Of Mckesson Corporation is also unsafe to use while breastfeeding. Below is detailed analysis of Simvastatin and Simvastatin | Mckesson Packaging Services A Business Unit Of Mckesson Corporation during location. We recommend you to go through provided detailed analysis as below take decision accordingly. We also recommend you talk to your health care provider before making final decision.
Statement of Manufacturer/Labeler about breastfeeding usage
8.3 Nursing Mothers It is not known whether simvastatin is excreted in human milk. Because a small amount of another drug in this class is excreted in human milk and because of the potential for serious adverse reactions in nursing infants, women taking simvastatin should not nurse their infants. A decision should be made whether to discontinue nursing or discontinue drug, taking into account the importance of the drug to the mother [see Contraindications (4)].
Simvastatin | Mckesson Packaging Services A Business Unit Of Mckesson Corporation Breastfeeding Analsys
Simvastatin while Breastfeeding Unsafe
CAS Number: 79902-63-9
Statins work by blocking cholesterol synthesis. At latest update no published data on breastfeeding were found. A high plasma protein-binding capacity makes it unlikely its passage into milk.Their low oral bioavailability hinders the passage toward infant’s plasma from ingested mother’s milk, except in preterm infants and immediate neonatal period, in which the infant may have an increased intestinal permeability. It is unknown whether it is capable of altering the lipid composition of milk, albeit it is known and that the infants need to ingest high amounts of cholesterol because it is essential for a proper development of cell membranes of the nervous system and as a precursor of various hormones and vitamins. It is prudent to avoid its use, at least while breastfeeding is exclusive. Atorvastatin is possibly the safest statin drug, for its high molecular weight makes it even more difficult the passage into the milk. With Pravastatin a poor secretion into milk has been reported. Simvastatin is the one with lowest oral bioavailability. Discontinuing the treatment of hypercholesterolemia during lactation with such kind of drugs will not likely alter the long-term outcome of the disease. A low-fat diet should be recommended.
Simvastatin | Mckesson Packaging Services A Business Unit Of Mckesson Corporation Breastfeeding Analsys - 2
Simvastatin while Breastfeeding
CAS Number: 79902-63-9
No relevant published information exists on the use of simvastatin during breastfeeding. Because of a concern with disruption of infant lipid metabolism, the consensus is that simvastatin should not be used during breastfeeding. However, others have argued that children homozygous for familial hypercholesterolemia are treated with statins beginning at 1 year of age, that statins have low oral bioavailability, and risks to the breastfed infant are low, especially with rosuvastatin and pravastatin. Until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
I already used Simvastatin | Mckesson Packaging Services A Business Unit Of Mckesson Corporation and meanwhile I breastfed my baby should I be concerned?
If you observer abnormal behavior or any other health issue in infant then you should immediately call 911 or contact other contact other emergency service provider in your area otherwise closely monitor the baby and inform your doctor about your Simvastatin | Mckesson Packaging Services A Business Unit Of Mckesson Corporation usage and time interval of breastfeeding.
My doctor has prescribed me Simvastatin | Mckesson Packaging Services A Business Unit Of Mckesson Corporation, what should I do?
If your doctor knows that you are breastfeeding mother and still prescribes Simvastatin | Mckesson Packaging Services A Business Unit Of Mckesson Corporation then there must be good reason for that as Simvastatin | Mckesson Packaging Services A Business Unit Of Mckesson Corporation is considered unsafe, It usually happens when doctor finds that overall advantage of taking outweighs the overall risk.
If I am using Simvastatin | Mckesson Packaging Services A Business Unit Of Mckesson Corporation, will my baby need extra monitoring?
Yes, Extra monitoring is required if mother is using Simvastatin | Mckesson Packaging Services A Business Unit Of Mckesson Corporation and breastfeeding as it is considered unsafe for baby.
Who can I talk to if I have questions about usage of Simvastatin | Mckesson Packaging Services A Business Unit Of Mckesson Corporation in breastfeeding?
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week